Quantcast

Latest Hepatic encephalopathy Stories

2011-03-01 07:07:00

PARIS, March 1, 2011 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb (NYSE:BMY) announced today that BARACLUDE(R) (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients with evidence of decompensated liver disease. BARACLUDE(r) was already approved in Europe in June 2006 for use in adult patients with CHB with compensated liver disease and evidence of active viral replication, persistently elevated serum...

2011-01-06 12:44:40

A pair of clinical trials, conducted in part at the University of North Carolina at Chapel Hill, found that two weeks of treatment with rifaximin provides significant relief of irritable bowel syndrome symptoms including bloating, abdominal pain and loose or watery stools. In addition, the studies found that the benefits of treatment with rifaximin (brand name: Xifaxan) persisted for 10 weeks after patients stopped taking the broad-spectrum antibiotic, said Yehuda Ringel, MD, an associate...

2011-01-06 09:35:21

(Ivanhoe Newswire) -- From constipation and diarrhea to bloating and abdominal pain, the estimated 30 million victims of irritable bowel syndrome in the United States have it tough. Now, recent testing of a new treatment called rifaximin offers hope for those struggling with the chronic condition. The antibiotic therapy was developed at Cedars-Sinai Medical Center in Los Angeles and was found to relieve patients of their painful symptoms during and after treatment -- often lasting for...

2010-12-15 07:00:00

SAN DIEGO, Dec. 15, 2010 /PRNewswire/ -- Ocera Therapeutics, Inc. announced today that it has completed two studies evaluating the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which includes healthy volunteers and patients with liver cirrhosis. OCR-002 recently received Orphan Drug status and Fast Track designation by the United States Food and Drug Administration for the treatment of hyperammonemia (excessive ammonia levels) and resultant Hepatic encephalopathy....

2010-05-07 13:15:07

Impairments more severe than early-stage Alzheimer's disease More than half of patients who have cirrhosis of the liver also display neurocognitive impairments such as short term memory loss, a study led by a Loyola University Health System researcher has found. Loyola neuropsychologist Christopher Randolph, PhD, and colleagues found that 54 percent of 301 cirrhosis patients who were tested scored below the 10th percentile for their age and education on a test that measures neurocognitive...

2010-05-04 12:59:44

Results confirm earlier Cedars-Sinai studies showing effectiveness of rifaximin against chronic IBS A targeted antibiotic provides effective and long-lasting relief of Irritable Bowel Syndrome symptoms, according to the results of two multisite Phase III clinical trials designed by Cedars-Sinai researchers. Rifaximin is the first drug treatment for IBS that relieves symptoms while it's being administered and continues to benefit patients after they stop taking the drug. Researchers found that...

2010-05-03 08:00:00

NEW ORLEANS, May 3 /PRNewswire/ -- Ocera Therapeutics, Inc. presented today an analysis of the prevalence of neurocognitive impairment in ambulatory cirrhotic patients at Digestive Disease Week (DDW), the annual meeting of the American Gastroenterological Association. The data, which came from the screening period of the ASTUTE Study demonstrated that 54% of the 301 cirrhotic patients screened had neurocognitive impairment. ASTUTE is an ongoing Phase 2b study evaluating the safety and...

2010-05-03 08:00:00

NEW ORLEANS, May 3 /PRNewswire/ -- Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary...

2010-04-27 14:09:18

Presence and type of complications predictors of mortality A recent study by Danish researchers discovered patients with alcoholic cirrhosis had a high prevalence of complications at the time of the disease diagnosis. Researchers noted that complications, such as ascites (excessive fluid in the abdomen), were predictors of mortality, but did not develop in a predictable sequence. Results of this 12-year mortality study appear in the May issue of Hepatology, a journal published by...

2010-04-16 14:28:47

Results show limited survival advantage, only in specific patient types Results from two studies presented today at the International Liver CongressTM 2010 have shown that treatment with extracorporeal devices may not confer a survival advantage for severe liver failure patients, despite positive dialysis effects. However, results among a small sub-group of patients show promise. Extracorporeal liver support therapy is in its infancy but is valued as a detoxification treatment option for...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related